(COO) The Cooper Companies - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 13.135m USD | Total Return: -5.1% in 12m
Avg Turnover: 213M
EPS Trend: 34.9%
Qual. Beats: 1
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
The Cooper Companies, Inc. (COO) is a global medical device manufacturer operating through two primary business segments: CooperVision and CooperSurgical. CooperVision focuses on the contact lens market, producing specialized spherical, toric, and multifocal lenses to correct conditions such as astigmatism and presbyopia. CooperSurgical provides medical devices and services for women’s healthcare, including fertility solutions, genomic services, and the Paragard intrauterine device.
The company operates within the Health Care Supplies sub-industry, a sector characterized by high barriers to entry due to stringent regulatory requirements and specialized manufacturing processes. Cooper’s business model relies on a diversified distribution network that targets hospitals, fertility clinics, and independent eye care professionals. For a deeper look into the companys valuation metrics, consider reviewing the detailed data on ValueRay. Headquartered in San Ramon, California, the company has maintained a presence in the medical technology market since 1958.
- Myopia management adoption rates drive long-term revenue growth in contact lens segment
- Expansion of fertility services portfolio increases high-margin CooperSurgical revenue share
- Global contact lens market share gains offset rising manufacturing and logistics costs
- Fluctuations in healthcare spending impact demand for elective women’s health procedures
- Regulatory approval timelines for new contact lens technologies influence investor valuation metrics
| Net Income: 235.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: 11.70% < 20% (prev 27.91%; Δ -16.21% < -1%) |
| CFO/TA 0.08 > 3% & CFO 953.0m > Net Income 235.8m |
| Net Debt (2.32b) to EBITDA (865.9m): 2.68 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago -2.84% < -2% |
| Gross Margin: 64.37% > 18% (prev 67.20%; Δ -2.83% > 0.5%) |
| Asset Turnover: 33.99% > 50% (prev 32.13%; Δ 1.86% > 0%) |
| Interest Coverage Ratio: 5.17 > 6 (EBIT TTM 481.2m / Interest Expense TTM 93.1m) |
| A: 0.04 (Total Current Assets 2.30b - Total Current Liabilities 1.80b) / Total Assets 12.5b |
| B: 0.62 (Retained Earnings 7.70b / Total Assets 12.5b) |
| C: 0.04 (EBIT TTM 481.2m / Avg Total Assets 12.4b) |
| D: 1.94 (Book Value of Equity 8.24b / Total Liabilities 4.24b) |
| Altman-Z'' = 4.57 = AA |
| DSRI: 0.98 (Receivables 809.2m/780.9m, Revenue 4.23b/3.99b) |
| GMI: 1.04 (GM 67.20% / 64.37%) |
| AQI: 0.96 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.06 (Revenue 4.23b / 3.99b) |
| TATA: -0.06 (NI 235.8m - CFO 953.0m) / TA 12.5b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of June 21, 2026, the stock is trading at USD 65.91 with a total of 3,802,105 shares traded.
Over the past week, the price has changed by -2.37%,
over one month by +7.26%,
over three months by -6.79% and
over the past year by -5.12%.
The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80.6 | 22.2% |
P/E Trailing = 57.0763
P/E Forward = 14.5138
P/S = 3.1045
P/B = 1.6041
P/EG = 0.6749
Revenue TTM = 4.23b USD
EBIT TTM = 481.2m USD
EBITDA TTM = 865.9m USD
Long Term Debt = 1.86b USD (from longTermDebt, last quarter)
Short Term Debt = 598.9m USD (from shortTermDebt, last quarter)
Debt = 2.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.50m
Net Debt = 2.32b USD (calculated: Debt 2.46b - CCE 138.8m)
Enterprise Value = 15.5b USD (13.1b + Debt 2.46b - CCE 138.8m)
Interest Coverage Ratio = 5.17 (Ebit TTM 481.2m / Interest Expense TTM 93.1m)
EV/FCF = 27.15x (Enterprise Value 15.5b / FCF TTM 569.5m)
FCF Yield = 3.68% (FCF TTM 569.5m / Enterprise Value 15.5b)
FCF Margin = 13.46% (FCF TTM 569.5m / Revenue TTM 4.23b)
Net Margin = 5.57% (Net Income TTM 235.8m / Revenue TTM 4.23b)
Gross Margin = 64.37% ((Revenue TTM 4.23b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Gross Margin QoQ = 68.00% (prev 67.88%)
Tobins Q-Ratio = 1.24 (Enterprise Value 15.5b / Total Assets 12.5b)
Interest Expense / Debt = 3.78% (Interest Expense 93.1m / Debt 2.46b)
Taxrate = 42.84% (176.7m / 412.5m)
NOPAT = 275.1m (EBIT 481.2m * (1 - 42.84%))
Current Ratio = 1.27 (Total Current Assets 2.30b / Total Current Liabilities 1.80b)
Debt / Equity = 0.30 (Debt 2.46b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.68 (Net Debt 2.32b / EBITDA 865.9m)
Debt / FCF = 4.08 (Net Debt 2.32b / FCF TTM 569.5m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.89% (Net Income 235.8m / Total Assets 12.5b)
RoE = 2.84% (Net Income TTM 235.8m / Total Stockholder Equity 8.30b)
RoCE = 4.74% (EBIT 481.2m / Capital Employed (Equity 8.30b + L.T.Debt 1.86b))
RoIC = 2.47% (NOPAT 275.1m / Invested Capital 11.1b)
WACC = 6.02% (E(13.1b)/V(15.6b) * Re(6.74%) + D(2.46b)/V(15.6b) * Rd(3.78%) * (1-Tc(0.43)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.46 | Cagr: -1.10%
[DCF] Terminal Value 77.97% ; FCFF base≈488.1m ; Y1≈559.5m ; Y5≈823.4m
[DCF] Fair Price = 51.62 (EV 12.4b - Net Debt 2.32b = Equity 10.1b / Shares 195.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 34.90 | EPS CAGR: 3.40% | SUE: 0.85 | # QB: 1
Revenue Correlation: 99.54 | Revenue CAGR: 6.75% | SUE: 3.79 | # QB: 1
EPS current Quarter (2026-07-31): EPS=1.12 | Chg30d=-5.89% | Revisions=-78% | Analysts=15
EPS current Year (2026-10-31): EPS=4.63 | Chg30d=+0.22% | Revisions=+23% | GrowthEPS=+12.3% | GrowthRev=+5.3%
EPS next Year (2027-10-31): EPS=5.00 | Chg30d=-0.41% | Revisions=-38% | GrowthEPS=+8.1% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -78%